

Aurealis Pharma to Attend 9th Annual Partnering Conference - Biotech Showcase, San Francisco, January 9-11th 2017

Basel Switzerland, Kuopio Finland – January 2nd 2017.

Aurealis Pharma, a privately owned biopharmaceutical company focused on developing novel lactic acid bacteria based “combination biologics in one product” for chronic inflammation and cancer patients, announced that CEO Juha Yrjänheikki will attend the 9th Annual Biotech Showcase Partnering Conference in San Francisco on January 9-11th 2017, and will present the company and its progression in one-on-one meetings with selected investors, pharma and biotech.

“We are pleased to attend and showcase our progress to investors. We had a busy year 2016 with a lot of milestones met in oncology and chronic inflammatory wound programs – AUP-16 in diabetic foot ulcer is entering GLP safety & toxicity studies and our cancer program has now two lead candidates selected with efficacy data available. We believe our progress will create excitement and interest within the biotech investor audience” said CEO Yrjänheikki.

Aurealis Pharma is a Basel Switzerland and Kuopio Finland based privately-held biopharmaceutical company focusing on developing broadly applicable proprietary technology to effectively, safely and economically modulate and re-educate the distorted host immune microenvironment to proper state in chronic inflammation and cancer. Company’s technology is based on safe food-grade lactic acid bacteria delivering multiple human therapeutic proteins in target tissue to address the unmet medical need in chronic wounds and cancer.

Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this critical week which is widely viewed as setting the tone for the coming year.

Now in its ninth year this rapidly growing conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. In addition to biopharmaceutical and life science company executives, Biotech Showcase delegates include investors in private and public companies, sector analysts, bankers and industry professionals.



AUREALIS PHARMA

Hochbergerstrasse 60C Microkatu 1
CH-4057 Basel FI-70210 Kuopio
Switzerland Finland
www.aurealispharma.com

Biotech Showcase is produced by Demy Colton Life Science Advisors and EBD Group. Both organizations have a long history of producing high quality programs that support the biotechnology and broader life sciences industry.

For more information:

Juha Yrjänheikki, CEO

Aurealis Pharma

Tel: +358 45 8433550

Email: [juha\(at\)aurealispharma.com](mailto:juha(at)aurealispharma.com)

www.aurealispharma.com



AUREALIS PHARMA

Hochbergerstrasse 60C Microkatu 1
CH-4057 Basel FI-70210 Kuopio
Switzerland Finland
www.aurealispharma.com